Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Intellia Therapeutics (NTLA) Leases (2019 - 2026)

Intellia Therapeutics has reported Leases over the past 8 years, most recently at $97.5 million for Q1 2026.

  • Quarterly Leases fell 29.31% to $97.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $97.5 million through Mar 2026, down 29.31% year-over-year, with the annual reading at $106.0 million for FY2025, 51.68% down from the prior year.
  • Leases was $97.5 million for Q1 2026 at Intellia Therapeutics, down from $106.0 million in the prior quarter.
  • Over five years, Leases peaked at $219.3 million in Q4 2024 and troughed at $73.8 million in Q2 2022.
  • The 5-year median for Leases is $115.4 million (2023), against an average of $117.3 million.
  • Year-over-year, Leases soared 5169.64% in 2022 and then tumbled 51.68% in 2025.
  • A 5-year view of Leases shows it stood at $133.1 million in 2022, then dropped by 13.3% to $115.4 million in 2023, then surged by 90.07% to $219.3 million in 2024, then tumbled by 51.68% to $106.0 million in 2025, then dropped by 7.94% to $97.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Leases are $97.5 million (Q1 2026), $106.0 million (Q4 2025), and $117.9 million (Q3 2025).